ACADIA PHARMACEUTICALS INC. Basic Shares Outstanding (Weighted Average)
ACADIA PHARMACEUTICALS INC. (ACAD) reported Basic Shares Outstanding (Weighted Average) of 171.60 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-05
- ACADIA PHARMACEUTICALS INC. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 171.60M shares, a 2.25% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 170.52M shares, a 2.22% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 169.91M shares, a 2.03% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 168.84M shares, a 1.72% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. weighted average number of shares outstanding, basic for fiscal 2025 was 168.36M shares, a 1.59% increase from fiscal 2024.
- ACADIA PHARMACEUTICALS INC. weighted average number of shares outstanding, basic for fiscal 2024 was 165.72M shares, a 1.16% increase from fiscal 2023.
- ACADIA PHARMACEUTICALS INC. weighted average number of shares outstanding, basic for fiscal 2023 was 163.82M shares, a 1.32% increase from fiscal 2022.
- ACADIA PHARMACEUTICALS INC. weighted average number of shares outstanding, basic for fiscal 2022 was 161.68M shares, a 100641.47% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 3 month as first filed | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 6 month as first filed | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 9 month as first filed | Weighted Average Number of Shares Outstanding, Basic 12 month | Weighted Average Number of Shares Outstanding, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 171.60M shares 10-Q · filed 2026-08-05 | 171.06M shares 10-Q · filed 2026-08-05 | 170.68M shares derived: average of 3 quarters · filed 2026-08-05 | 170.22M shares derived: average of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | 170.52M shares 10-Q · filed 2026-05-07 | 170.22M shares derived: average of 2 quarters · filed 2026-05-07 | 169.76M shares derived: average of 3 quarters · filed 2026-05-07 | 169.27M shares derived: average of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | 169.91M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 169.37M shares derived: average of 2 quarters · filed 2026-02-26 | 168.86M shares derived: average of 3 quarters · filed 2026-08-05 | 168.36M shares 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | 168.84M shares 10-Q · filed 2025-11-06 | 168.33M shares derived: average of 2 quarters · filed 2026-08-05 | 167.84M shares 10-Q · filed 2025-11-06 | 167.50M shares derived: average of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | 167.83M shares 10-Q · filed 2026-08-05 | 167.32M shares 10-Q · filed 2026-08-05 | 167.32K shares 10-Q · filed 2025-08-07 | 167.06M shares derived: average of 3 quarters · filed 2026-08-05 | 166.79M shares derived: average of 4 quarters · filed 2026-08-05 | |||
| 2025-03-31 | 166.81M shares 10-Q · filed 2026-05-07 | 166.67M shares derived: average of 2 quarters · filed 2026-05-07 | 166.44M shares derived: average of 3 quarters · filed 2026-05-07 | 166.22M shares derived: average of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | 166.54M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 166.26M shares derived: average of 2 quarters · filed 2026-02-26 | 166.02M shares derived: average of 3 quarters · filed 2026-02-26 | 165.72M shares 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | 165.97M shares 10-Q · filed 2025-11-06 | 165.76M shares derived: average of 2 quarters · filed 2025-11-06 | 165.44M shares 10-Q · filed 2025-11-06 | 165.28M shares derived: average of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | 165.55M shares 10-Q · filed 2025-08-07 | 165.17K shares 10-Q · filed 2025-08-07 | 165.17M shares 10-Q · filed 2024-08-07 | 165.05M shares derived: average of 3 quarters · filed 2026-02-26 | 164.85M shares derived: average of 4 quarters · filed 2026-02-26 | |||
| 2024-03-31 | 164.80M shares 10-Q · filed 2025-05-08 | 164.81M shares derived: average of 2 quarters · filed 2026-02-26 | 164.61M shares derived: average of 3 quarters · filed 2026-02-26 | 164.33M shares derived: average of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | 164.81M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 164.52M shares derived: average of 2 quarters · filed 2026-02-26 | 164.17M shares derived: average of 3 quarters · filed 2026-02-26 | 163.82M shares 10-K · filed 2026-02-26 | 163.82K shares 10-K · filed 2024-02-28 | |||
| 2023-09-30 | 164.23M shares 10-Q · filed 2024-11-07 | 164.23K shares 10-Q · filed 2023-11-03 | 163.85M shares derived: average of 2 quarters · filed 2024-11-07 | 163.49M shares 10-Q · filed 2024-11-07 | 163.49K shares 10-Q · filed 2023-11-03 | 284.05M shares derived: average of 4 quarters · filed 2025-02-27 | ||
| 2023-06-30 | 163.46M shares 10-Q · filed 2024-08-07 | 163.46K shares 10-Q · filed 2023-08-03 | 163.11M shares 10-Q · filed 2024-08-07 | 163.11K shares 10-Q · filed 2023-08-03 | 323.99M shares derived: average of 3 quarters · filed 2025-02-27 | 243.03M shares derived: average of 4 quarters · filed 2025-02-27 | ||
| 2023-03-31 | 162.26M shares 10-Q · filed 2024-05-09 | 404.26M shares derived: average of 2 quarters · filed 2025-02-27 | 269.56M shares derived: average of 3 quarters · filed 2025-02-27 | 202.21M shares derived: average of 4 quarters · filed 2025-02-27 | ||||
| 2022-12-31 | 646.25M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 323.20M shares derived: average of 2 quarters · filed 2025-02-27 | 215.52M shares derived: average of 3 quarters · filed 2025-02-27 | 161.68M shares 10-K · filed 2025-02-27 | 161.68K shares 10-K · filed 2023-02-28 | |||
| 2022-09-30 | 161.85K shares 10-Q · filed 2023-11-03 | 161.75K shares derived: average of 2 quarters · filed 2023-11-03 | 161.58K shares 10-Q · filed 2023-11-03 | 40.43M shares derived: average of 4 quarters · filed 2024-02-28 | ||||
| 2022-06-30 | 161.65K shares 10-Q · filed 2023-08-03 | 161.44K shares 10-Q · filed 2023-08-03 | 53.85M shares derived: average of 3 quarters · filed 2024-02-28 | 40.43M shares derived: average of 4 quarters · filed 2024-02-28 | ||||
| 2022-03-31 | 161.23M shares 10-Q · filed 2023-05-08 | 80.70M shares derived: average of 2 quarters · filed 2024-02-28 | 53.85M shares derived: average of 3 quarters · filed 2024-02-28 | 40.43M shares derived: average of 4 quarters · filed 2024-02-28 | ||||
| 2021-12-31 | 163.02K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | 161.84K shares derived: average of 2 quarters · filed 2024-02-28 | 161.37K shares derived: average of 3 quarters · filed 2024-02-28 | 160.49K shares 10-K · filed 2024-02-28 | ||||
| 2021-09-30 | 160.66K shares 10-Q · filed 2022-11-03 | 160.54K shares derived: average of 2 quarters · filed 2022-11-03 | 159.65K shares 10-Q · filed 2022-11-03 | |||||
| 2021-06-30 | 160.42K shares 10-Q · filed 2022-08-09 | 160.22K shares 10-Q · filed 2022-08-09 | ||||||
| 2020-12-31 | 157.33K shares 10-K · filed 2023-02-28 | |||||||
| 2012-12-31 | 55.12M shares 10-K · filed 2013-03-12 | |||||||
| 2011-12-31 | 52.18M shares 10-K · filed 2013-03-12 | |||||||
| 2010-12-31 | 38.59M shares 10-K · filed 2013-03-12 | |||||||
| 2009-12-31 | 37.48M shares 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |